Labeled leukocyte imaging

Current status and future directions

C. J. Palestro, Charito Love, K. K. Bhargava

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

The ability to radiolabel inflammatory cells that migrate to foci of infection was a significant milestone in the evolution of infection imaging. More than 20 years after being approved for clinical use in the United States, labeled leukocyte imaging using cells labeled with [99mTc]exametazime or [111In]oxine remains the radionuclide procedure of choice for diagnosing most infections in the immunocompetent population. In the central nervous system, labeled leukocyte imaging is useful for differentiating infection from tumor; in the post-operative setting, this test facilitates the differentiation of infection from normal postoperative changes. Labeled leukocyte imaging accurately diagnoses mycotic aneurysms and infected prosthetic vascular grafts. In patients with fever of unknown origin, a negative study excludes, with a high degree of certainty, infection as the source of fever. Labeled leukocyte imaging accurately diagnoses pedal osteomyelitis and is useful for distinguishing infection from the neuropathic joint in this population. Together with bone marrow imaging, the labeled leukocyte study is the imaging procedure of choice for diagnosing prosthetic joint infection. There are limitations to the test most of the leukocytes labeled are neutrophils, and the procedure is most useful for detecting neutrophil-mediated inflammatory processes, i.e., bacterial infections. It is less useful for illnesses in which the predominant cellular response is other than neutrophilic, such as most opportunistic infections and spinal osteomyelitis. The in vitro labeling procedure is time consuming and is not routinely available. Results of in vivo leukocyte labeling methods have been variable; none are available in the United States. Labeled leukocyte imaging suffers from inherently poor quality images. Single photon emission compute tomography/computed tomography improves lesion localization, and will undoubtedly improve the accuracy of the test. Efforts to develop methods of labeling white cells with positron emitting compounds are underway and, if successful, should further strengthen the role of nuclear medicine in infection imaging.

Original languageEnglish (US)
Pages (from-to)105-123
Number of pages19
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
Volume53
Issue number1
StatePublished - Feb 2009
Externally publishedYes

Fingerprint

Leukocytes
Infection
Osteomyelitis
Neutrophils
Joints
Infected Aneurysm
Fever of Unknown Origin
Direction compound
Nuclear Medicine
Opportunistic Infections
Single-Photon Emission-Computed Tomography
Bacterial Infections
Radioisotopes
Population
Blood Vessels
Foot
Fever
Central Nervous System
Bone Marrow
Tomography

Keywords

  • Leukocytes
  • Radiolabelling
  • Radionuclide imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Labeled leukocyte imaging : Current status and future directions. / Palestro, C. J.; Love, Charito; Bhargava, K. K.

In: Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 53, No. 1, 02.2009, p. 105-123.

Research output: Contribution to journalArticle

@article{023503fe60ab4ad89faa79f988bfd457,
title = "Labeled leukocyte imaging: Current status and future directions",
abstract = "The ability to radiolabel inflammatory cells that migrate to foci of infection was a significant milestone in the evolution of infection imaging. More than 20 years after being approved for clinical use in the United States, labeled leukocyte imaging using cells labeled with [99mTc]exametazime or [111In]oxine remains the radionuclide procedure of choice for diagnosing most infections in the immunocompetent population. In the central nervous system, labeled leukocyte imaging is useful for differentiating infection from tumor; in the post-operative setting, this test facilitates the differentiation of infection from normal postoperative changes. Labeled leukocyte imaging accurately diagnoses mycotic aneurysms and infected prosthetic vascular grafts. In patients with fever of unknown origin, a negative study excludes, with a high degree of certainty, infection as the source of fever. Labeled leukocyte imaging accurately diagnoses pedal osteomyelitis and is useful for distinguishing infection from the neuropathic joint in this population. Together with bone marrow imaging, the labeled leukocyte study is the imaging procedure of choice for diagnosing prosthetic joint infection. There are limitations to the test most of the leukocytes labeled are neutrophils, and the procedure is most useful for detecting neutrophil-mediated inflammatory processes, i.e., bacterial infections. It is less useful for illnesses in which the predominant cellular response is other than neutrophilic, such as most opportunistic infections and spinal osteomyelitis. The in vitro labeling procedure is time consuming and is not routinely available. Results of in vivo leukocyte labeling methods have been variable; none are available in the United States. Labeled leukocyte imaging suffers from inherently poor quality images. Single photon emission compute tomography/computed tomography improves lesion localization, and will undoubtedly improve the accuracy of the test. Efforts to develop methods of labeling white cells with positron emitting compounds are underway and, if successful, should further strengthen the role of nuclear medicine in infection imaging.",
keywords = "Leukocytes, Radiolabelling, Radionuclide imaging",
author = "Palestro, {C. J.} and Charito Love and Bhargava, {K. K.}",
year = "2009",
month = "2",
language = "English (US)",
volume = "53",
pages = "105--123",
journal = "Quarterly Journal of Nuclear Medicine and Molecular Imaging",
issn = "1824-4785",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Labeled leukocyte imaging

T2 - Current status and future directions

AU - Palestro, C. J.

AU - Love, Charito

AU - Bhargava, K. K.

PY - 2009/2

Y1 - 2009/2

N2 - The ability to radiolabel inflammatory cells that migrate to foci of infection was a significant milestone in the evolution of infection imaging. More than 20 years after being approved for clinical use in the United States, labeled leukocyte imaging using cells labeled with [99mTc]exametazime or [111In]oxine remains the radionuclide procedure of choice for diagnosing most infections in the immunocompetent population. In the central nervous system, labeled leukocyte imaging is useful for differentiating infection from tumor; in the post-operative setting, this test facilitates the differentiation of infection from normal postoperative changes. Labeled leukocyte imaging accurately diagnoses mycotic aneurysms and infected prosthetic vascular grafts. In patients with fever of unknown origin, a negative study excludes, with a high degree of certainty, infection as the source of fever. Labeled leukocyte imaging accurately diagnoses pedal osteomyelitis and is useful for distinguishing infection from the neuropathic joint in this population. Together with bone marrow imaging, the labeled leukocyte study is the imaging procedure of choice for diagnosing prosthetic joint infection. There are limitations to the test most of the leukocytes labeled are neutrophils, and the procedure is most useful for detecting neutrophil-mediated inflammatory processes, i.e., bacterial infections. It is less useful for illnesses in which the predominant cellular response is other than neutrophilic, such as most opportunistic infections and spinal osteomyelitis. The in vitro labeling procedure is time consuming and is not routinely available. Results of in vivo leukocyte labeling methods have been variable; none are available in the United States. Labeled leukocyte imaging suffers from inherently poor quality images. Single photon emission compute tomography/computed tomography improves lesion localization, and will undoubtedly improve the accuracy of the test. Efforts to develop methods of labeling white cells with positron emitting compounds are underway and, if successful, should further strengthen the role of nuclear medicine in infection imaging.

AB - The ability to radiolabel inflammatory cells that migrate to foci of infection was a significant milestone in the evolution of infection imaging. More than 20 years after being approved for clinical use in the United States, labeled leukocyte imaging using cells labeled with [99mTc]exametazime or [111In]oxine remains the radionuclide procedure of choice for diagnosing most infections in the immunocompetent population. In the central nervous system, labeled leukocyte imaging is useful for differentiating infection from tumor; in the post-operative setting, this test facilitates the differentiation of infection from normal postoperative changes. Labeled leukocyte imaging accurately diagnoses mycotic aneurysms and infected prosthetic vascular grafts. In patients with fever of unknown origin, a negative study excludes, with a high degree of certainty, infection as the source of fever. Labeled leukocyte imaging accurately diagnoses pedal osteomyelitis and is useful for distinguishing infection from the neuropathic joint in this population. Together with bone marrow imaging, the labeled leukocyte study is the imaging procedure of choice for diagnosing prosthetic joint infection. There are limitations to the test most of the leukocytes labeled are neutrophils, and the procedure is most useful for detecting neutrophil-mediated inflammatory processes, i.e., bacterial infections. It is less useful for illnesses in which the predominant cellular response is other than neutrophilic, such as most opportunistic infections and spinal osteomyelitis. The in vitro labeling procedure is time consuming and is not routinely available. Results of in vivo leukocyte labeling methods have been variable; none are available in the United States. Labeled leukocyte imaging suffers from inherently poor quality images. Single photon emission compute tomography/computed tomography improves lesion localization, and will undoubtedly improve the accuracy of the test. Efforts to develop methods of labeling white cells with positron emitting compounds are underway and, if successful, should further strengthen the role of nuclear medicine in infection imaging.

KW - Leukocytes

KW - Radiolabelling

KW - Radionuclide imaging

UR - http://www.scopus.com/inward/record.url?scp=65749106527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65749106527&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 105

EP - 123

JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging

JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging

SN - 1824-4785

IS - 1

ER -